Wall Street analysts expect AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) to post earnings of ($0.26) per share for the current quarter, according to Zacks. Three analysts have made estimates for AcelRx Pharmaceuticals’ earnings, with estimates ranging from ($0.30) to ($0.22). AcelRx Pharmaceuticals posted earnings per share of ($0.25) in the same quarter last year, which suggests a negative year-over-year growth rate of 4%. The firm is scheduled to report its next quarterly earnings results on Tuesday, November 7th.
According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year earnings of ($1.13) per share for the current year, with EPS estimates ranging from ($1.20) to ($1.02). For the next financial year, analysts expect that the firm will report earnings of ($0.84) per share, with EPS estimates ranging from ($1.31) to ($0.64). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover AcelRx Pharmaceuticals.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.01). The business had revenue of $2.66 million during the quarter, compared to analysts’ expectations of $2.63 million.
A number of equities analysts have issued reports on the stock. Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 1st. Royal Bank Of Canada set a $6.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 25th. Stifel Nicolaus upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th. Finally, Piper Jaffray Companies set a $3.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $8.75.
Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) traded up 3.431% during mid-day trading on Friday, reaching $5.275. The company’s stock had a trading volume of 1,566,803 shares. AcelRx Pharmaceuticals has a 12 month low of $1.95 and a 12 month high of $5.75. The firm’s market cap is $239.38 million. The company’s 50-day moving average is $3.62 and its 200 day moving average is $2.93.
In related news, insider Pamela P. Palmer purchased 10,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Tuesday, August 22nd. The shares were bought at an average price of $2.95 per share, for a total transaction of $29,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Lawrence G. Hamel sold 10,161 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $5.29, for a total transaction of $53,751.69. Following the transaction, the insider now owns 16,379 shares in the company, valued at approximately $86,644.91. The disclosure for this sale can be found here. Insiders have purchased 37,000 shares of company stock worth $112,280 in the last quarter. 28.10% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its position in shares of AcelRx Pharmaceuticals by 6.6% during the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares during the period. Teachers Advisors LLC increased its position in shares of AcelRx Pharmaceuticals by 14.6% during the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 8,475 shares during the period. WealthTrust Axiom LLC increased its position in shares of AcelRx Pharmaceuticals by 50.0% during the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after buying an additional 70,000 shares during the period. Virtu KCG Holdings LLC increased its position in shares of AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares during the period. Finally, LMR Partners LLP purchased a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at about $319,000. Institutional investors own 23.32% of the company’s stock.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.